EP 4137136 A1 20230222 - DOSING REGIMENS ASSOCIATED WITH EXTENDED RELEASE PALIPERIDONE INJECTABLE FORMULATIONS
Title (en)
DOSING REGIMENS ASSOCIATED WITH EXTENDED RELEASE PALIPERIDONE INJECTABLE FORMULATIONS
Title (de)
DOSIERUNGSSCHEMATA IN VERBINDUNG MIT INJIZIERBAREN PALIPERIDONFORMULIERUNGEN MIT VERLÄNGERTER FREISETZUNG
Title (fr)
SCHÉMAS POSOLOGIQUES ASSOCIÉS À DES FORMULATIONS INJECTABLES DE PALIPÉRIDONE À LIBÉRATION PROLONGÉE
Publication
Application
Priority
US 202163235331 P 20210820
Abstract (en)
The present invention provides methods of treating patients with long acting injectable paliperidone palmitate formulations. The disclosure includes methods for mitigating at least one adverse change in blood lipid levels of a patient in need thereof who has been treated with a paliperidone palmitate extended-release injectable suspension at either one-month intervals (PP1M) or three-month intervals (PP3M), comprising transitioning the patient to a paliperidone palmitate extended-release injectable suspension having a six month dosing interval (PP6M).
IPC 8 full level
A61K 31/519 (2006.01); A61P 3/06 (2006.01); A61P 25/18 (2006.01)
CPC (source: EP IL KR US)
A61K 9/0019 (2013.01 - IL KR US); A61K 9/10 (2013.01 - IL KR US); A61K 31/519 (2013.01 - EP IL KR US); A61K 47/10 (2013.01 - IL KR US); A61K 47/26 (2013.01 - IL KR US); A61P 3/06 (2018.01 - EP IL); A61P 25/18 (2018.01 - EP IL KR); A61K 9/0019 (2013.01 - EP); A61K 9/10 (2013.01 - EP); A61K 47/10 (2013.01 - EP); A61K 47/26 (2013.01 - EP)
Citation (applicant)
- US 6077843 A 20000620 - FRANCOIS MARC KAREL JOZEF [BE], et al
- US 6555544 B2 20030429 - FRANCOIS MARC KAREL JOZEF [BE], et al
- US 9439906 B2 20160913 - VERMEULEN AN [BE], et al
- US 10143693 B2 20181204 - GOPAL SRIHARI [US], et al
- US 5254556 A 19931019 - JANSSEN CORNELUS G M [BE], et al
- WO 2006114384 A1 20061102 - JANSSEN PHARMACEUTICA NV [BE], et al
- "Handbook of Pharmaceutical Excipients", 1986, PHARMACEUTICAL PRESS
- "Diagnostic and Statistical Manual of Mental Disorders", 2013, AMERICAN PSYCHIATRIC ASSOCIATION
Citation (search report)
- [Y] PEITL VJEKOSLAV ET AL: "Paliperidone Palmitate 6-month (PP6M)", vol. 57, no. 2, 1 June 2021 (2021-06-01), pages 229 - 232, XP055982664, ISSN: 2671-1079, Retrieved from the Internet <URL:https://hrcak.srce.hr/file/374365> DOI: 10.20471/dec.2021.57.02.13
- [Y] ANONYMOUS: "U.S. FDA Approves INVEGA TRINZA, First and Only Four-Times-A-Year Treatment for Schizophrenia", JOHNSON & JOHNSON, 19 May 2019 (2019-05-19), XP055627214, Retrieved from the Internet <URL:https://www.jnj.com/media-center/press-releases/us-fda-approves-invega-trinza-first-and-only-four-times-a-year-treatment-for-schizophrenia> [retrieved on 20190930]
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
EP 4137136 A1 20230222; AU 2022329095 A1 20240404; CA 3229731 A1 20230223; CN 118119394 A 20240531; IL 310909 A 20240401; KR 20240049580 A 20240416; US 2023077039 A1 20230309; WO 2023021008 A1 20230223
DOCDB simple family (application)
EP 22190434 A 20220815; AU 2022329095 A 20220815; CA 3229731 A 20220815; CN 202280069874 A 20220815; EP 2022072793 W 20220815; IL 31090924 A 20240218; KR 20247008812 A 20220815; US 202217887826 A 20220815